Organogenesis Holdings (ORGO) Total Non-Current Liabilities (2017 - 2026)
Organogenesis Holdings (ORGO) posted quarterly Total Non-Current Liabilities of $137.2 million for Q1 2026, up 39.35% year-over-year from $98.4 million in Q1 2025, and down 16.17% quarter-over-quarter from $163.6 million in Q4 2025.
Organogenesis Holdings (ORGO) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Organogenesis Holdings' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $137.2 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 39.35% year-over-year to $137.2 million; the TTM figure through Mar 2026 stood at $137.2 million (up 39.35% YoY), while the FY2025 annual figure was $163.6 million, up 46.51% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $137.2 million, down from $163.6 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $202.0 million in Q2 2022, with the low at $96.9 million in Q2 2025.
- The 5-year median for Total Non-Current Liabilities is $178.4 million (2024), against an average of $162.1 million.
- Peak annual rise in Total Non-Current Liabilities reached 46.51% in 2025, while the deepest fall reached 45.69% in 2025.
- Organogenesis Holdings' Total Non-Current Liabilities stood at $182.6 million in 2022, then declined by 1.32% to $180.1 million in 2023, then sank by 38.01% to $111.7 million in 2024, then jumped by 46.51% to $163.6 million in 2025, then fell by 16.17% to $137.2 million in 2026.
- Business Quant data shows ORGO's Total Non-Current Liabilities at $137.2 million in Q1 2026, $163.6 million in Q4 2025, and $121.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Organogenesis Holdings | 238.69 Mn | 191.85 Mn | 20.08 Mn | 114.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 114.60 Mn |
| Mar 31, 2026 | 137.16 Mn |
| Dec 31, 2025 | 163.62 Mn |
| Sep 30, 2025 | 121.34 Mn |
| Jun 30, 2025 | 96.89 Mn |
| Mar 31, 2025 | 98.43 Mn |
| Dec 31, 2024 | 111.68 Mn |
| Sep 30, 2024 | 166.46 Mn |
| Jun 30, 2024 | 178.39 Mn |
| Mar 31, 2024 | 179.21 Mn |
| Dec 31, 2023 | 180.15 Mn |
| Sep 30, 2023 | 184.59 Mn |
| Jun 30, 2023 | 177.84 Mn |
| Mar 31, 2023 | 181.26 Mn |
| Dec 31, 2022 | 182.57 Mn |
| Sep 30, 2022 | 199.85 Mn |
| Jun 30, 2022 | 201.97 Mn |
| Mar 31, 2022 | 193.68 Mn |
| Dec 31, 2021 | 200.37 Mn |
| Sep 30, 2021 | 181.25 Mn |